Increase in p21cip1/waf1 and concomitant decrease in CDK activity by bortezomib are found responsible for sensitization of bladder and prostate cancer cells to TRAIL-induced apoptosis 33. This evidence concerns the gene CDKN1A and prostate carcinoma.